The AAFP, at all times, supports rigorous pre- and post-market testing of drugs, devices, and biological agents. Testing should ensure safety as well as benefit measured by health outcomes of value to patients. Testing should also ensure adequate representation in clinical research of populations that are historically and/or currently underrepresented in primary medical literature.
Previously approved agents should be available for research or scientifically supported clinical use for "off label" indications. The selection of appropirate agents in treatment of an individual should take into consideration the scientific evidence alongside the patient's values and preferences in a shared decision-making process. (1977) (October 2023 COD)